Indications |
Oral Susceptible infections Adult: 500 mg tid. May increase to 1 g tid in fulminating infections. Child: <1 yr: About 15 mg/kg; 1-5 yr: 250 mg; 5-12 yr: 500 mg. Doses to be taken tid. Intravenous Susceptible infections Adult: >50 kg: 500 mg tid; may increase to 1 g tid in fulminating infections. <50 kg: 6-7 mg/kg tid. To be given by slow IV infusion over at least 2 hr; should be given via a large vein with good blood flow. Child: 20 mg/kg daily in 3 divided doses. To be given by slow IV infusion over at least 2 hr; should be given via a large vein with good blood flow. Ophthalmic Conjunctivitis Adult: As 1% eye drops: Instill 1 drop into the affected eye every 12 hr for 7 days. Child: ≥2 yr: As 1% eye drops: Instill 1 drop into the affected eye every 12 hr for 7 days. Topical/Cutaneous Skin infections Adult: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily. Child: As a 2% ointment/cream/gel: Apply onto affected area 3-4 times daily until there is improvement. If gauze dressing is used, then frequency of application may be reduced to 1-2 times daily. Reconstitution: Each 500 mg dose is given as a buffered solution (pH 7.4-7.6) diluted to 500 ml with sodium chloride or other suitable IV solution. Incompatibility: Incompatible with amino acid solutions or whole blood. Admixture incompatibility: Carbenicillin, kanamycin, gentamicin, calcium solutions. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Hepatic disease; monitor liver function. Neonates; pregnancy, lactation. |
Adverse Reactions |
Jaundice and liver dysfunction (reversible); GI disturbances. IV: Venospasm, thrombophloebitis and haemolysis; hypocalcaemia. SC/IM: Tissue necrosis. Topical: Rashes and irritation. |
Drug Interactions |
Synergistic action with antistaphylococcal penicillin. Antagonism with ciprofloxacin. See Below for More fusidic acid Drug Interactions |
Food Interactions |
Delays absorption for oral preparations. |
Mechanism of Actions |
Fusidic acid disrupts translocation of peptide subunits and elongating the peptide chain of susceptible bacteria, thus inhibiting protein synthesis. Absorption: Well-absorbed from the GI tract (oral); mean plasma concentrations of 30 mcg/ml after 2-4 hr (500-mg dose). More rapid absorption in children than in adults. Distribution: Widely distributed into tissues and body fluids including bone, pus and synovial fluid; crosses the placenta and enters breast milk. Protein-binding: 95%. Metabolism: Hepatic; converted to multiple metabolites. Excretion: Bile (mainly as metabolites), faeces (2% as unchanged drug), urine; 5-6 hr (elimination half-life). |
Administration |
Fusidic acid: Should be taken with food. |
Storage Conditions |
Intravenous: Store below 25°C. Ophthalmic: Store between 2-25°C. Discard 1 mth after opening. Oral: Store below 25°C. Topical/Cutaneous: Store below 25°C. |
ATC Classification |
D06AX01 - fusidic acid ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases. D09AA02 - fusidic acid ; Belongs to the class of ointment dressings with antiinfectives. J01XC01 - fusidic acid ; Belongs to the class of steroid antibacterials. Used in the systemic treatment of infections. S01AA13 - fusidic acid ; Belongs to the class of antibiotics. Used in the treatment of eye infections. |
Storage |
Intravenous: Store below 25°C. Ophthalmic: Store between 2-25°C. Discard 1 mth after opening. Oral: Store below 25°C. Topical/Cutaneous: Store below 25°C. |
Available As |
|
Fusidic Acid
Post Review about Fusidic Acid Click here to cancel reply.
Fusidic Acid Containing Brands
Fusidic Acid is used in following diseases
Drug - Drug Interactions of Fusidic Acid
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.